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Abstract
Background: To examine the role of inflammatory mediators in neuropathic pain, we used a
replication-defective genomic herpes simplex virus (HSV)-based vector containing the coding
sequence for the anti-inflammatory peptide interleukin (IL)-4 under the transcriptional control of
the HSV ICP4 immediate early promoter, vector S4IL4, to express IL-4 in dorsal root ganglion
(DRG) neurons in vivo.
Results: Subcutaneous inoculation of S4IL4 in the foot transduced lumbar DRG to produce IL-4.
Transgene-mediated expression of IL-4 did not alter thermal latency or tactile threshold in normal
animals, but inoculation of S4IL4 1 week after spinal nerve ligation (SNL) reduced mechanical
allodynia and reversed thermal hyperalgesia resulting from SNL. Inoculation of S4IL4 1 week before
SNL delayed the development of thermal hyperalgesia and tactile allodynia, but did not prevent the
ultimate development of these manifestations of neuropathic pain. S4IL4 inoculation suppressed
non-noxious-induced expression of c-Fos immunoreactivity in dorsal horn of spinal cord and
reversed the upregulation of spinal IL-1β, PGE2, and phosphorylated-p38 MAP kinase,
characteristic of neuropathic pain.
Conclusion: HSV-mediated expression of IL-4 effectively reduces the behavioral manifestations of
neuropathic pain, and reverses some of the biochemical and histologic correlates of neuropathic
pain at the spinal level.
Background
Neural-immune interactions play a key role in the patho-
genesis of neuropathic pain. Partial nerve injury results in
the release of proinflammatory cytokines interleukin (IL)-
1β, IL-6, and tumor necrosis factor alpha from activated
Schwann cells, endothelial cells, and macrophages in
nerve [1] to produce direct effects on nociceptive activity
[2]. Peripheral nerve damage also activates microglia and
astrocytes in spinal cord to release the same proinflamma-
tory cytokines in dorsal horn [3-6], resulting in central
sensitization [7,8] and an exaggerated pain response char-
acteristic of neuropathic pain [9-11].
IL-4 is a prototypical anti-inflammatory cytokine that
modulates macrophage activity through global suppres-
sion of proinflammatory cytokines [12-14], in addition to
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pleiotropic effects on the development of immune cells
and the immune response [15]. The broad spectrum of IL-
4 action makes it an attractive candidate for suppressing
cytokine activation in neuropathic pain, but the short
half-life of the peptide and its pleiotropic effects on
immune responsiveness preclude the use of systemic IL-4
for the treatment of pain.
Gene transfer provides the opportunity to produce the
release of short-lived peptides in restricted distributions in
the nervous system [16,17]. Transduction of sensory neu-
rons of the dorsal root ganglion (DRG) by footpad inocu-
lation of recombinant herpes simplex virus (HSV)-based
vectors can be used to achieve the local release of neu-
ropeptides from the central and peripheral terminals of
primary afferents in dorsal horn of spinal cord [18-20].
Gene transfer to DRG by HSV vectors coding for
proenkephalin produces an anti-hyperalgesic effect in
models of acute thermal nociception, provides an anti-
nociceptive effect in subacute inflammatory and neuro-
pathic pain, and reduces both nociceptive behavior and
joint destruction in a rodent model of arthritis [18-21].
HSV-mediated release of proenkephalin or the glial cell
line-derived neurotrophic factor from DRG neurons pro-
vides an analgesic effect in the spinal nerve ligation (SNL)
model of neuropathic pain [22,23], and an HSV vector
expressing glutamic acid decarboxylase produces gamma-
aminobutyric acid to provide an anti-nociceptive effect in
the rodent model of chronic spinal cord injury pain [24].
To examine the role of inflammatory cytokines in the SNL
model of neuropathic pain, we used an HSV vector
expressing the anti-inflammatory cytokine IL-4 delivered
to the DRG by subcutaneous inoculation in the foot. We
found that HSV-mediated expression of IL-4 reduced
mechanical allodynia and thermal hyperalgesia and
reduced the induction of c-Fos-like immunoreactivity
(Fos-LI) by non-noxious touch, and also blocked the
increase in expression of IL-1β, PGE2, and phosphor-
ylated p38 (p-p38) in the spinal cord after SNL.
Results
S4IL4 produces IL-4 in vitro and in vivo
Transduction of primary DRG neurons in culture with
S4IL4 (Figure 1a) at a multiplicity of infection (MOI) of 1
resulted in the production and release of substantial
amounts of IL-4 into the medium as detected by ELISA
(110 pg/ml over 24 hrs from cells infected with S4IL4
compared to 10 pg/ml from cells infected with control
vector SHZ). Rats inoculated subcutaneously in the foot
with 30 µl of S4IL4 containing 4 × 108 pfu 1 week after L5
SNL and sacrificed 2 weeks later had 23.7 pg IL-4 per
DRG, compared to no detectable IL-4 in SHZ-inoculated
animals. Immunofluorescent staining of DRG 1 week
(a) Schematic representation of vector S4IL4 Figure 1
(a) Schematic representation of vector S4IL4. The control vector SHZ was identical to S4IL4, except that the inserted cassette 
contained the E. coli lacZ reporter gene under the control of the HCMV IEp in the tk locus. (b) Immunofluorescent staining 
shows IL-4 expression in large and small neurons in the DRG 1 week after subcutaneous inoculation of vector S4IL4.
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after vector inoculation revealed that IL-4 immunoreactiv-
ity was found in both large and small neurons in the DRG
(Figure 1b).
Anti-nociceptive effect of inoculation of S4IL4
Vector-mediated IL-4 production did not affect normal
sensory function. Unoperated animals inoculated with
either S4IL4 or SHZ showed no change in mechanical
threshold or withdrawal latency to thermal stimulus com-
pared to animals without vector inoculation over the
course of 3 weeks (data not shown). L5 SNL resulted in
tactile allodynia manifested by a decrease in withdrawal
threshold to tactile stimuli from 11 ± 1 to 1.9 ± 0.1 g. Ani-
mals inoculated with S4IL4 1 week after SNL showed a
statistically significant reduction in mechanical allodynia
that was continuous and sustained. This was first observed
in animals tested 3 d after inoculation and for 5 weeks,
peaking at 2 weeks after the inoculation (Figure 2a). By 6
weeks after inoculation, the effect of vector inoculation
was no longer apparent and the mechanical threshold of
the S4IL4-injected rats was indistinguishable from that of
SHZ-inoculated controls (Figure 2a). Reinoculation of
S4IL4 into the foot after the anti-allodynic effect had
waned resulted in reestablishment of the anti-allodynic
Antinociceptive effect of S4IL4 in rats with neuropathic pain resulting from SNL Figure 2
Antinociceptive effect of S4IL4 in rats with neuropathic pain resulting from SNL. Filled diamonds – S4IL4; open squares – SHZ; 
open triangles – vehicle control. Mechanical allodynia is identical in vehicle control and SHZ-inoculated animals [21]. Values 
presented as mean ± SEM, n = 6–8 animals per group. Arrows indicate time of vector inoculation. X-axis: weeks after SNL. In 
each case, P < 0.01 comparing S4IL4-inoculated to control, using the general linear model (GLM) for repeated measures. (a) 
Mechanical allodynia in animals inoculated with vector 1 week after SNL. (b) Thermal hyperalgesia in animals inoculated with 
vector 1 week after SNL. (c) Mechanical allodynia in animals inoculated with the vector 1 week prior to SNL. (d) Thermal 
hyperalgesia in animals inoculated with the vector 1 week prior to SNL.
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effect, which appeared to be of greater magnitude than the
original anti-allodynic effect with a similar duration. Vec-
tor-mediated IL-4 expression also reduced thermal hyper-
algesia. SNL reduced the mean withdrawal latency to
radiant heat from 11 ± 0.4 to 7 ± 0.3 s, a phenomenon
that gradually resolved spontaneously over the course of 5
weeks (Figure 2b). Inoculation with S4IL4 but not SHZ
resulted in a significant reversal of thermal hyperalgesia
compared to vehicle-injected animals (Figure 2b). The
effect of vector-mediated transgene expression on thermal
hyperalgesia was statistically significant by 1 week and
maximal by 2 weeks after inoculation.
Previous studies have suggested that proinflammatory
cytokines may play a role in the initiation of neuropathic
pain [3-6]; therefore, we were interested to determine
whether expression of IL-4 prior to the time of spinal
nerve injury would prevent the development of neuro-
pathic pain. A set of animals was inoculated with the vec-
tor 1 week prior to SNL, preventing both mechanical
allodynia and thermal hyperalgesia (Figures 2c, 2d). The
magnitude of the anti-allodynic effect of prior inoculation
of the vector was greater than that seen with a single inoc-
ulation performed 1 week after SNL. Nonetheless, by 5
weeks after SNL, the anti-allodynic effect of the vector was
substantially reduced, and by 6 weeks after inoculation
the S4IL4-inoculated animals were indistinguishable
from the SHZ-inoculated controls. These results suggest
that IL-4 served to suppress pain-related behaviors, but
did not prevent initiation of neuropathic pain. Prior inoc-
ulation of the vector also prevented thermal hyperalgesia
after the SNL, but because control animals recover by 4–5
Fos-LI was induced 3 weeks after operation using 10 min of  gentle tactile stimulation; animals were sacrificed 2 h later Figure 3
Fos-LI was induced 3 weeks after operation using 10 min of 
gentle tactile stimulation; animals were sacrificed 2 h later. 
Rats inoculated with SHZ (a) 1 week after SNL show a 
marked increase in Fos-LI-positive neurons compared with 
those inoculated with S4IL4 (b). (c) Quantitative distribution 
of Fos-LI neurons in laminae of the L4–5 dorsal horn. Results 
are expressed as the mean ± SEM numbers of Fos-LI neurons 
per section (*P < 0.05 compared to SHZ-inoculated; n = 5, 
ANOVA).
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IL-1β, PGE2, and p-p38 expression in the spinal cord dorsal  horn in neuropathic rats Figure 4
IL-1β, PGE2, and p-p38 expression in the spinal cord dorsal 
horn in neuropathic rats. Rats were given gentle tactile stim-
ulation to left paw for 10 min 3 weeks after SNL or sham 
surgery. Ipsilateral dorsal horn was harvested 2 h after gentle 
stimulation. Inoculation of S4IL4 but not control vector sig-
nificantly suppressed the increase in levels of IL-1β (a), PGE2 
(b), and p-p38α (c) (all values in pg/mg wet weight of tissue; 
*P < 0.05, **P < 0.01, ANOVA, post-hoc Scheffe test). (d) 
Double immunofluorescence demonstrates colocalization of 
p-p38 (red) with the microglial marker OX-42 (green) in 
dorsal horn 3 weeks after SNL. P-p38 did not colocalize with 
NeuN in spinal dorsal horn (data not shown).
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weeks, the duration of the effect of vector pre-inoculation
on thermal hyperalgesia could not be assessed.
Effect of S4IL4 inoculation on Fos-LI in the spinal cord
Non-noxious touch-induced expression of c-Fos in the
dorsal horn provides a histologic marker of nociceptive
processing in the dorsal horn (Figures 3a, 3b). Animals
inoculated with S4IL4 showed a substantial reduction in
the number of c-Fos immunoreactive neurons after non-
noxious touch in both superficial (I-II) and deeper (III-IV)
laminae of the dorsal horn compared to vehicle or SHZ-
inoculated SNL animals (Figure 3c).
Effect of S4IL4 inoculation on spinal IL-1β, PGE2, and p-
p38
SNL significantly increases levels of IL-1β, PGE2, and p-
p38 in dorsal horn of spinal cord ipsilateral to the nerve
injury. Animals inoculated with S4IL4 1 week after SNL
showed a substantial reduction in the levels of IL-1β (Fig-
ure 4a) and PGE2 (Figure 4b) compared to animals inoc-
ulated after SNL with control vector SHZ. The level of p-
p38α increased dramatically after SNL; this increase was
prevented in animals inoculated with S4IL4 (Figure 4c).
To identify the cell types that expressed p-p38 after SNL,
we performed double-label immunostaining of p-p38
with NeuN (neurons) and OX-42 (CD-11b, microglia).
Most of the p-p38 immunostaining appeared to be in the
nuclei of microglia, based on the colocalization of p-p38
immmunoreactivity with the marker OX-42 (Figure 4d).
p-ERK was also increased in the spinal horn of rats follow-
ing SNL, but this increase was not suppressed in animals
inoculated with S4IL4 (data not shown).
Discussion
There are 3 principal results from the current study. First,
the HSV-based vector S4IL4 produced IL-4 in vitro, and in
vivo in DRG neurons following transfection by subcuta-
neous inoculation. Second, IL-4 released from DRG neu-
rons transduced with S4IL4 in vivo reduced pain-related
behavior, which correlated with a reduction in non-nox-
ious touch-induced c-Fos expression in dorsal horn in the
SNL model of neuropathic pain. Finally, S4IL4-mediated
IL-4 release decreased the levels of IL-1β and PGE2 in dor-
sal horn, and reduced the phosphorylation of spinal p-
p38.
The role of inflammatory cytokines in the development of
inflammatory (nociceptive) pain has been recognized for
some time [25]. More recent evidence has demonstrated
that proinflammatory cytokines, including IL-1β, induce a
long-term alteration of synaptic transmission in the cen-
tral nervous system, and that spinal expression and release
of these cytokines plays a critical role in the development
and maintenance of neuropathic pain of peripheral origin
[3-6]. Inflammatory cytokines increase in nerve after
peripheral nerve injury as well [26], and several different
antagonists of proinflammatory cytokine effects can
reverse allodynia in the neuropathic pain model in rats
[5,6,27].
IL-4 is a prototypical anti-inflammatory cytokine that is
known to increase IL-1 receptor antagonist mRNA and
protein, and to suppress the expression of IL-1β mRNA
and IL-1β protein in vitro [28]. IL-4 directly inhibits the
induction of nitric oxide synthase and levels of cyclooxy-
genase 2, the enzymes responsible for the production of
nitric oxide and PGE2, respectively [29]. In models of
inflammatory pain, intraplantar administration of IL-4
peptide reduces pain caused by subsequent intraplantar
injection of carageeninin, bradykinin or TNFα [30], and
itraperitoneal administration of IL-4 peptide produces a
transient reduction in pain-related behavior, measured by
the writhing response in mice and by zymosan-induced
knee joint incapacitation in rats [31]. In the experiments
that are the subject of the current report, we have demon-
strated that transgene-mediated expression of IL-4 in DRG
effectively reduces nocifensive behaviors and blocks
expression of IL-1β in spinal cord, in the neuropathic pain
model induced by the peripheral nerve injury (SNL).
Activation of mitogen-activated protein kinases, including
extracellular signal-related kinase and p38, contribute to
the development and maintenance of pain hypersensitiv-
ity through transcription-dependent and transcription-
independent pathways [32-34]. Activated p38 participates
in the maintenance of inflammatory heat hyperalgesia
[35], p-p38 is increased in non-neuronal cells in the spi-
nal cord after nerve injury, and in vitro application of IL-
1β induces phosphorylation and activation of p38
mitogen-activated protein kinase. IL-4 produced by sub-
cutaneous inoculation of S4IL4 suppressed expression of
p-p38 but not pERK in the dorsal horn.
The time course of the analgesic effect of vector-mediated
IL-4 observed in this study is similar to the time course on
the analgesic effects that we have observed in experiments
using HSV-mediated gene transfer to DRG to produce the
release of enkephalin [20,21]and GABA [24,36]. We
believe it is most likely that the transient time course of
the analgesic effect reflects the time course of transgene
expression characteristic of the viral immediate early gene
promoters [37] that we have employed in these vectors;
the HSV ICP4 promoter in vector S4IL4 in the current
study, and the human cytomegalovirus immediate early
promoter (HCMV IEp) in the enkephalin- and GABA-pro-
ducing vectors. In the current study as in those previous
studies we have observed that reinoculation of the vector
after the effect has waned produces an effect that is at least
equivalent to, and appears to be greater than, the effect
produced by the initial inoculation of the vector. TheMolecular Pain 2006, 2:6 http://www.molecularpain.com/content/2/1/6
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design of the studies does not allow for a direct statistical
comparison of the effect of the second inoculation to that
produced by the first; the observation that the effective-
ness of the vector is not reduced following reinoculation
suggests that there is no significant immune response to
the initial vector inoculation in these models.
The observation that intrathecal administration of an
anti-IL-6 antibody and IgG [38], the anti-inflammatory
cytokine IL-10 [39], or a combination of IL-1 receptor
antagonist and the soluble tumor necrosis factor receptor
[40] in models of peripheral neuropathic pain reduce
nocifensive behaviors, supports the contention that spinal
expression of inflammatory mediators plays a role in the
spinal sensitization characteristic of chronic neuropathic
pain. A peripheral action of proinflammatory cytokines in
the pathogenesis neuropathic pain have also been defined
in model systems [41]. In the gene transfer experiments
reported herein we have not established the locus of
action of the HSV-mediated IL-4. IL-4 produced in the
DRG is transported both centrally (towards the spinal
cord) and peripherally (towards the skin) in the bipolar
axon of the sensory neuron, and the experiments per-
formed do not allow us to distinguish the effects of IL-4 in
the nerve from effects that occur at the level of the spinal
cord. Gene transfer to meninges by intrathecal inocula-
tion of IL-2 using an adenovirus vector [42] or IL-10 using
an adeno-associated gene transfer vector [43] reduces pain
in the chronic constriction injury model of neuropathic
pain. Compared to adeno-associated viral vector gene
transfer to the meninges, HSV-mediated gene transfer has
2 advantages: restricted release of the peptide into the spi-
nal cord via distribution into central projections of the
transduced neurons provides an anti-inflammatory effect
restricted to the region where spinal inflammation related
to pain occurs, and axonal transport of the peptide from
the DRG into nerve may provide additional reduction in
pain-generating mechanisms. Wherever the effect occurs,
effective treatment of chronic neuropathic pain will need
to be directed at the prevention or reversal of the proin-
flammatory state in the dorsal horn. In this regard, HSV-
mediated release of anti-inflammatory cytokines may be
particularly useful in the development of novel treatments
for human regional neuropathic pain syndromes.
Materials and methods
Construction of the IL-4-expressing HSV vector
S4IL4 (Figure 1a) was generated as described [44] by Cre-
lox recombination of a plasmid containing the HSV ICP4
promoter, murine IL-4, an HCMV-β-galactosidase expres-
sion cassette and a lox recombination site [45] into the
thymidine kinase locus of d120 [46] which is a KOS strain
HSV with a deletion in both copies of the immediate-early
ICP4 [47]. Recombinants were screened by X-gal staining
for β-galactosidase expression and purified by 3 rounds of
limiting dilution. Viral constructs were verified by South-
ern blot analysis, propagated, and purified as described
[48]. Control vector SHZ (Figure 1a) is similar to S4IL4,
but contains only lacZ under the control of the human
cytomegalovirus immediate-early promoter in the thymi-
dine kinase locus.
Expression of IL-4 in vitro
DRG neurons from 17-day-old embryonic rats were cul-
tured on polylysine-coated coverslips in B27/Neurobasal
medium, Glutamax II, AlbuMAX, and nerve growth factor
(NGF) supplementation. At 14 d in vitro, the cells were
infected for 1 h with either S4IL4 or SHZ at an MOI of 1,
and the medium changed to fresh medium without NGF.
Twenty-four hrs postinfection the medium was collected
and the amount of IL-4 determined by ELISA (R&D Sys-
tems, Minneapolis, MN).
Experimental animals and surgical procedures
Male Sprague-Dawley rats weighing 225–250 g were used.
All housing conditions and experimental procedures were
approved by the Institutional Animal Care and Use Com-
mittee. Under chloral hydrate anesthesia, one-third of the
left L6 transverse process was removed and nerve injury
was produced by tight ligation of the L5 spinal nerve using
6-0 silk suture [49]. Sham control animals were treated
identically, except that the spinal nerve was not ligated.
Rats with SNL exhibited a change in the ipsilateral foot
position and displayed a "guarding behavior" of ipsilat-
eral hind limb, but animals displaying motor dysfunction
of the proximal hind limb after operation were excluded
from further analysis. All the animals exhibited normal
weight gain, toenail growth, and level of activity. One
week after the operation the rats were inoculated subcuta-
neously in the plantar surface of the left hind paw with 30
µl of S4IL4 or control vector SHZ at a concentration of 4
× 108 plaque-forming units/ml. There was no evidence of
distress or abnormally aggressive behavior in any of the
animals after inoculation with HSV vector.
Behavioral testing
Mechanical allodynia
Rats were placed in transparent plastic cubicles on a mesh
floor for an acclimatization period of at least 30 min.
Mechanical allodynia induced by L5 SNL was determined
by assessing paw withdrawal to von Frey hairs of graded
tensile strength. A series of calibrated von Frey filaments
(0.4, 0.7, 1.2, 1.5, 2.0, 3.6, 5.5, 8.5, 11.8, and 15.1 g) were
presented serially to the hind paw in ascending order of
strength, with each filament applied for 6 s with sufficient
force to cause slight bending against the paw. A positive
response, defined as rapid withdrawal and/or licking of
the paw immediately upon application of the stimulus,
was followed by application of the next finer von Frey fil-
ament. After a negative response, the next higher von FreyMolecular Pain 2006, 2:6 http://www.molecularpain.com/content/2/1/6
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filament was applied. Animals that did not respond to a
pressure of 15.1 g were assigned to this cut off value. The
tactile stimulus producing a 50% likelihood of with-
drawal was determined using the up-down method
[50,51].
Thermal hyperalgesia
The latency to hind paw withdrawal from a thermal stim-
ulus was determined by exposing the plantar surface of
the hind paw to radiant heat using a modified Hargreaves
thermal testing device [52]. Briefly, rats were placed in
individual enclosures on a glass plate maintained at 30°C
and a radiant thermal stimulus was positioned under-
neath the glass plate directly under the hind paw. Activa-
tion of the bulb simultaneously activated a timer, and
both were immediately turned off by paw withdrawal or
at the 20 s cut-off time.
Immunohistochemistry
Expression of c-Fos was induced by gentle touch applied
once every 4 s for 10 min, as was previously described
[53,54]. Each stimulus was moved from the middle of the
foot to the distal footpad over the course of 2 s in a man-
ner that would not elicit a flexion reflex in normal rats.
Two hours following completion of stimulation, the ani-
mals were deeply anesthetized with chloral hydrate and
perfused through the heart with 300 ml saline followed by
500 ml of 4% paraformaldehyde in 0.1 M phosphate buff-
ered saline (PBS). The spinal cord was post-fixed for 4 h,
cryo-protected in 30% sucrose in PBS, and 35 µm trans-
verse sections of L4–L5 segments incubated overnight at
4°C with the primary antibody (anti-c-Fos, 1:500 or anti-
pERK1/2, 1:200; Santa Cruz Biotechnology, Inc., Santa
Cruz, CA, or anti OX-42, 1:1000, BD Biosciences, San
Jose, CA). This was followed by the secondary antibody
(biotinylated goat anti-rabbit IgG, 1:100; Vector Labora-
tories, Burlingame, CA) and detected using the Vectastain
Elite ABC Kit (Vector Laboratories) as described [23,55].
The sections were developed with diaminobenzidine
(DAB Substrate Kit; Vector Laboratories) for 2 to 6 min,
then washed with PBS before being mounted onto gela-
tin-coated slides, dehydrated, and coverslipped. Ten sec-
tions from each rat were randomly selected and the
expression of Fos-LI and pERK1/2 evaluated by a blinded
observer counting the number of immunopositive neu-
rons in the gray matter of ipsilateral spinal cord.
Immunofluorescent staining
Spinal sections prepared as described above were incu-
bated with the primary antibody (anti-p-p38, 1:150, Cell
Signaling Technology, Beverly, MA) overnight at 4°C, fol-
lowed by a CY-3 conjugated secondary antibody for 1 h at
room temperature. For double-label fluorescence, spinal
sections were incubated with a mixture of polyclonal anti-
p-p38 and anti-NeuN (1: 500, Chemicon International,
Temecula, CA) or OX-42 (BD Pharmigen 1:500, BD Bio-
sciences, San Jose, CA) over 2 nights at 4°C, followed by
a mixture of CY3 or Alexafluor 488 conjugated secondary
antibodies (Molecular Probes, Eugene, OR) for 1 h at
room temperature. The stained sections were examined
using an Olympus Fluoview BX61 confocal microscope
(Olympus America, Melville, NY).
ELISA
Quantitative evaluation of IL-4 protein expression in vivo
was determined by ELISA. One week after selective L5 SNL
animals were inoculated with either S4IL4 or SHZ as
described above. Two weeks after inoculation, the L4 DRG
were removed, frozen on dry ice, and stored at -80°C. The
tissue was minced and placed in 0.3 ml of ice-cold
homogenization buffer (50 mM NaCl, 10 mM Tris, 2.5
mM MgCl2, pH 7.4) containing 1 protease inhibitor cock-
tail tablet (Roche, Mannheim, Germany) per 50 ml, as
described previously [23]. To determine the amount of IL-
1β, PGE2, and p-p38α in other animals the ipsilateral dor-
sal quadrant of lumbar spinal cord was processed in an
identical fashion and peptide levels determined using spe-
cific ELISA kits (R&D Systems).
Data analysis
All data presented as mean ± SEM. The statistical signifi-
cance of differences between groups was evaluated by
ANOVA, using Scheffe's post-hoc test. For repeated meas-
ures of behavioral function, parametric statistics, using
the general linear model (GLM) for repeated measures
were used to identify significant effects of treatment con-
dition on the behavioral measure of neuropathic pain.
The results were examined for a main effect of treatment
group. All statistical analyses were performed using the
software package, SPSS 13.0 for Windows (SPSS Inc., Chi-
cago, Illinois).
Conclusion
These experiments demonstrate that expression of IL-4 in
DRG neurons, achieved by HSV-mediated gene transfer in
vivo, reduces mechanical allodynia and thermal hyperal-
gesia in the SNL model of neuropathic pain. Inoculation
of S4IL4 1 week before SNL delayed the development of
thermal hyperalgesia and tactile allodynia, but did not
prevent manifestations of neuropathic pain. S4IL4 inocu-
lation suppressed non-noxious-induced expression of c-
Fos immunoreactivity in dorsal horn of spinal cord, and
reversed the upregulation of spinal IL-1β, PGE2, and p-
p38 MAP kinase, characteristic of neuropathic pain.
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HSV herpes simplex virus
IL interleukin
MOI multiplicity of infection
NGF nerve growth factor
PBS phosphate buffered saline
p-p38 phosphorylated p-38
SNL spinal nerve ligation
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